Jefferies raised the firm’s price target on HealthEquity (HQY) to $118 from $95 and keeps a Buy rating on the shares. Estimates have risen in recent quarters and the firm now sees less room for upside in the second half of FY25 and FY26 relative to the current maturity ladder. However, it believes Robert F. Kennedy Jr., the current nominee for Secretary of HHS, represents “a potential step change” for the market who could potentially increases the total addressable market by as much as four times, noting that in an op-ed for the WSJ in early September, he outlined potential policy ideas including to “increase patient choice by giving every American a health savings account.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HQY:
- HealthEquity initiated with a Neutral at Goldman Sachs
- HealthEquity price target raised to $130 from $110 at BTIG
- HealthEquity price target raised to $120 from $100 at BofA
- HealthEquity CEO Transition: Jon Kessler to Scott Cutler
- HealthEquity CEO Jon Kessler to retire, Scott Cutler to succeed
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
